<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900636</url>
  </required_header>
  <id_info>
    <org_study_id>317/19</org_study_id>
    <nct_id>NCT04900636</nct_id>
  </id_info>
  <brief_title>Telemedicine for Patients With an Hybrid Closed Loop System</brief_title>
  <official_title>A Telemedicine Platform for Patients With Type 1 Diabetes Mellitus Treated With an Hybrid Closed Loop System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the impact on quality of life after a follow-up program&#xD;
      using a telemedicine platform designed for patients with DM1 treated with an hybrid closed&#xD;
      loop insulin infusion system. Open-label, randomized 1:1 controlled clinical trial during 12&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Health-related quality of life in patients with type 1 diabetes (the ViDa1 questionnaire). The four-dimensional structure for ViDa1 are:&#xD;
Interference of diabetes in everyday life (the minimum value: 12 and maximum value: 60) higher scores mean a worse outcome&#xD;
Self-care (the minimum value: 11 and maximum value: 55) higher scores mean a better outcome&#xD;
Well-being (the minimum value: 6 and maximum value: 30) higher scores mean a better outcome, and&#xD;
Worry about the disease (the minimum value: 5 and maximum value: 25) higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>12 months</time_frame>
    <description>A1c levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Telemedicine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of a telemedicine platform combined with face-to-face visits according to protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional follow-up according to routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Telemedicine Arm</intervention_name>
    <description>Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.</description>
    <arm_group_label>Telemedicine Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic criteria for DM1 according to ADA&#xD;
&#xD;
          -  They must have access to the technology that allows monitoring (mobile phone and / or&#xD;
             computer as well as having an internet connection)&#xD;
&#xD;
          -  Acceptance of participation in the study and signing of the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gestation&#xD;
&#xD;
          -  Institutionalization, serious or terminal illness or renal replacement therapy.&#xD;
&#xD;
          -  Inability to undertake the training and / or acquire the degree of knowledge to use&#xD;
             the telemedicine platform.&#xD;
&#xD;
          -  Refusal to participate in the study or to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lía Nattero Chávez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ramón y CajaDiabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lía Nattero Chávez, MD PhD</last_name>
    <phone>+34913369029</phone>
    <email>marialia.nattero@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Luque Ramirez, MD PhD</last_name>
    <phone>+34913369029</phone>
    <email>manuel.luque@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lía Nattero Chávez</name>
      <address>
        <city>Madrid</city>
        <state>Please Select</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lía Nattero Chávez, MD PhD</last_name>
      <phone>+34913369029</phone>
      <email>marialia.nattero@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

